Literature DB >> 10938492

First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group.

J Vítovec1, J Spinar.   

Abstract

BACKGROUND: First-dose hypotension refers to an observed reduction in blood pressure after the administration of the first dose of ACE inhibitors in patients with congestive heart failure. AIM: To compare the first-dose responses of low-dose enalapril and perindopril in patients with stable symptomatic chronic heart failure.
METHODS: Single blind, randomised, multicenter, parallel, prospective study. Patients (N=298) with chronic heart failure due to ischemic heart disease or dilated cardiomyopathy, NYHA II-IV, ejection fraction<40%, age>18 years, naive to ACE inhibitors or ATI-receptor blocker, were randomised to receive a single dose of 2. 5 mg enalapril or 2.0 mg perindopril. Baseline laboratory and clinical examinations were performed before entry into the study. Ambulatory blood pressure monitoring started 2 h before the study medication was given, and continued for at least 10 h after the medication.
RESULTS: The maximum drop in blood pressure appeared approximately 4 h after dose administration in both groups, and was more pronounced in the enalapril group. Patients in the enalapril group had a significantly higher incidence of asymptomatic hypotension. No symptomatic hypotension requiring a change in medication or a prolongation of hospitalisation was observed.
CONCLUSION: A low dose of perindopril is well-tolerated at initiation of ACE inhibitor therapy in patients with chronic heart failure and causes less first-dose hypotension than a low dose of enalapril.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10938492     DOI: 10.1016/s1388-9842(00)00095-7

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  7 in total

Review 1.  A benefit-risk assessment of agents used in the secondary prevention of stroke.

Authors:  Ronald S MacWalter; Colin P Shirley
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.

Authors:  Monique P Curran; Paul L McCormack; Dene Simpson
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Prolonged First-Dose Hypotension Induced by Sacubitril/Valsartan.

Authors:  Fu-Chih Hsiao; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2018-01       Impact factor: 2.672

Review 4.  Perindopril: in congestive heart failure.

Authors:  Dene Simpson; Stuart Noble; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  DDIGIP: predicting drug-drug interactions based on Gaussian interaction profile kernels.

Authors:  Cheng Yan; Guihua Duan; Yi Pan; Fang-Xiang Wu; Jianxin Wang
Journal:  BMC Bioinformatics       Date:  2019-12-24       Impact factor: 3.169

6.  Perindopril for improving cardiovascular events.

Authors:  James J DiNicolantonio; James H O'Keefe
Journal:  Vasc Health Risk Manag       Date:  2014-08-30

7.  Cardiac and renal function interactions in heart failure with reduced ejection fraction: A mathematical modeling analysis.

Authors:  Hongtao Yu; Sanchita Basu; K Melissa Hallow
Journal:  PLoS Comput Biol       Date:  2020-08-17       Impact factor: 4.475

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.